1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 7
2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 9
2.3 Upcoming Related Reports 9
3 Epidemiology 10
3.1 Disease Background 10
3.2 Risk Factors and Comorbidities 11
3.2.1 Increased age is associated with increased risk and worsened prognosis 12
3.2.2 Smoking increases the risk of M2 AML 13
3.2.3 APL is relatively common among Spanish and Italian origins 13
3.2.4 Chemotherapy and radiation therapy increases the risk of AML 14
3.2.5 Benzene increases risk of AML 14
3.3 Global Trends 15
3.3.1 Incidence 15
3.3.2 Survival and Prevalence 18
3.3.3 Subtypes and Mutations 19
3.3.4 Risk Groups 21
3.4 Forecast Methodology 24
3.4.1 Sources Used 25
3.4.2 Forecast Assumptions and Methods 32
3.4.3 Sources not Used 38
3.5 Epidemiological Forecast for Acute Myeloid Leukemia (2014-2024) 39
3.5.1 Adjusted Diagnosed Incident Cases of AML 39
3.5.2 Adjusted Diagnosed Incident Cases of AML by Age 41
3.5.3 Adjusted Diagnosed Incident Cases of AML by Sex 43
3.5.4 Age-Standardized Incidence of AML 44
3.5.5 APL and MDS/Therapy Related AML 45
3.5.6 APL and MDS/Therapy Related AML by Age 49
3.5.7 Diagnosed Incident Cases of AML with FLT3 Mutations 51
3.5.8 Diagnosed Incident Cases of AML by Risk Group Classifications 52
3.5.9 Five-Year Diagnosed Prevalent Cases of AML 55
3.5.10 Five-Year Diagnosed Prevalent Cases of AML by Age 57
3.5.11 Five-Year Diagnosed Prevalent Cases of APL and MDS/Therapy-Related AML 58
3.5.12 Five-Year Diagnosed Prevalent Cases of APL and MDS/Therapy-Related AML by Age 59
3.6 Discussion 60
3.6.1 Epidemiological Forecast Insight 60
3.6.2 Limitations of the Analysis 61
3.6.3 Strengths of the Analysis 62
4 Appendix 63
4.1 Bibliography 63
4.2 About the Authors 69
4.2.1 Epidemiologists 69
4.2.2 Reviewers 70
4.2.3 Global Director of Therapy Analysis and Epidemiology 70
4.2.4 Global Head of Healthcare 71
4.3 About GlobalData 72
4.4 About EpiCast 72
4.5 Disclaimer 73
Table 1: Risk Factors for AML in Adults 12
Table 2: Incidence of AML per 100,000 Population in Japan, 1993-2002, All Ages 17
Table 3: Estimated Frequencies of Cytogenetic Abnormalities in AML 22
Table 4: Risk Group Classification Guidelines 23
Table 5: 7MM, Sources of AML Diagnosed Incidence 25
Table 6: 7MM, Adjusted Diagnosed Incident Cases of AML, Both Sexes, Ages ≥20 Years, N, Selected Years, 2014-2024 40
Table 7: 7MM, Adjusted Diagnosed Incident Cases of AML by Age, Both Sexes, N (Row %), 2014 41
Table 8: 7MM, Adjusted Diagnosed Incident Cases of AML by Sex, N (Row %), 2014 43
Table 9: 7MM, Diagnosed Incident Cases of APL, Both Sexes, Ages ≥20 Years, N, Selected Years, 2014-2024 46
Table 10: 7MM, Diagnosed Incident Cases of MDS/Therapy-related AML, Both Sexes, Ages ≥20 Years, N, Selected Years, 2014-2024 47
Table 11: 7MM, Diagnosed Incident Cases of AML Subtypes by Age, Both Sexes, N (Row % in Each Subtype), 2014 49
Table 12: 7MM, Diagnosed Incident Cases of AML with FLT3 Mutations, Both Sexes, Ages ≥20 Years, N, Selected Years 2014-2024 51
Table 13: 7MM, Diagnosed Incident Cases of AML by Risk Group Classification, Both Sexes, Ages ≥20 Years, N (Row %), 2014 52
Table 14: US, Risk Group Classification of AML Incident Cases by Age, Both Sexes, N (Row %), 2014 54
Table 15: 7MM, Five-Year Diagnosed Prevalent Cases of AML, Both Sexes, Ages ≥20 Years, N, Selected Years, 2014-2024 55
Table 16: 7MM, Five-Year Diagnosed Prevalent Cases of AML by Age, Both Sexes, N (Row %), 2014 57
Table 17: 7MM, Five-Year Diagnosed Prevalent Cases of APL, Both Sexes, Ages ≥20 Years, N, Selected Years, 2014-2024 58
Table 18: 7MM, Five-Year Diagnosed Prevalent Cases of MDS/Therapy-Related AML, Both Sexes, Ages ≥20 Years, N, Selected Years, 2014-2024 59
Table 19: 7MM, Five-Year Diagnosed Prevalent Cases of AML Subtypes by Age, Both Sexes, N (Row %), 2014 60
1.2 List of Figures
Figure 1: 7MM, Adjusted Diagnosed Incident Cases of AML, Both Sexes, Ages ≥20 Years, N, 2014-2024 40
Figure 2: 7MM, Adjusted Diagnosed Incident Cases of AML by Age, Both Sexes, Ages ≥20 Years, N, 2014 42
Figure 3: 7MM, Adjusted Diagnosed Incident Cases of AML by Sex, Ages ≥20 Years, N, 2014 44
Figure 4: 7MM, Age-Standardized Adjusted Diagnosed Incidence of AML, Ages ≥20 Years, 2014 45
Figure 5: 7MM, Diagnosed Incident Cases of APL, and MDS/Therapy-Related AML, Both Sexes, Ages ≥20 Years, N, 2014 and 2024 48
Figure 6: 7MM, Diagnosed Incident Cases of AML Subtypes by Age, Both Sexes, N, 2014 50
Figure 7: 7MM, Diagnosed Incident Cases of AML by Risk Group Classification, Both Sexes, Ages ≥20 Years, N, 2014 53
Figure 8: US, Risk Group Classification of AML Incident Cases by Age, Both Sexes, N, 2014 54
Figure 9: 7MM, Five-Year Diagnosed Prevalent Cases of AML, Both Sexes, Ages ≥20 Years, N, 2014-2024 56
【レポートのキーワード】
急性骨髄性白血病（AML）、疫学調査
